<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01320579</url>
  </required_header>
  <id_info>
    <org_study_id>CL09002</org_study_id>
    <secondary_id>2010-023543-15</secondary_id>
    <nct_id>NCT01320579</nct_id>
  </id_info>
  <brief_title>Investigation of the Efficacy of 2.5% and 5% Cis-urocanic Acid in Patients With Moderate or Severe Atopic Dermatitis</brief_title>
  <official_title>Phase II Study to Investigate the Properties of Topical Twice Daily Doses of 2.5% and 5% Cis-urocanic Acid in Comparison to Active Comparator 0.1% Protopic® for up to 28 Days in Patients With Moderate or Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioCis Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioCis Pharma Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate dose response, safety, tolerability and efficacy of&#xD;
      2.5% and 5% cis-UCA in comparison to placebo and active comparator in the treatment of adult&#xD;
      patients with moderate or severe chronic atopic dermatitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II multi-centre, double-blinded, vehicle-controlled, repeated and multiple&#xD;
      dose, study to evaluate dose response, safety, tolerability and efficacy of 2.5% and 5%&#xD;
      cis-UCA compared to placebo, and investigator-blinded to compare the safety, tolerability and&#xD;
      efficacy of cis-UCA to the active comparator Protopic® 0.1% in patients with moderate or&#xD;
      severe chronic atopic dermatitis treated for up to 28 days.&#xD;
&#xD;
      The primary objective is to compare the efficacy of two different doses of cis-UCA (2.5% and&#xD;
      5%) with placebo for up to 28 days in adult patients with moderate or severe chronic atopic&#xD;
      dermatitis to determine the dose of cis-UCA for further clinical development.&#xD;
&#xD;
      Secondary objectives are as follows:&#xD;
&#xD;
        -  To evaluate safety and tolerability of cis-UCA after topical twice daily doses of 2.5%&#xD;
           and 5% for up to 28 days in adult patients with moderate or severe chronic atopic&#xD;
           dermatitis.&#xD;
&#xD;
        -  To evaluate dose response after topical twice daily doses of 2.5% and 5% for up to 28&#xD;
           days in adult subjects with moderate or severe chronic atopic dermatitis.&#xD;
&#xD;
        -  To compare the efficacy and safety of 2.5% and 5% of cis-UCA to the efficacy and safety&#xD;
           of 0.1% Protopic® after topical twice daily doses for up to 28 days in adult patients&#xD;
           with moderate or severe chronic atopic dermatitis&#xD;
&#xD;
      The key eligibility criteria are the following: patients with moderate or severe chronic&#xD;
      atopic dermatitis, at least 18 years of age, with no current treatment for atopic dermatitis&#xD;
      with active systemic medication or active topical treatment in the planned investigational&#xD;
      area, and with no history of any significant disease that would affect the use of cis-UCA or&#xD;
      comparator.&#xD;
&#xD;
      In total, up to 150 adult patients (both males and females; at least 20% of each gender) with&#xD;
      moderate or severe chronic atopic dermatitis will be included in the study. Up to 36 adult&#xD;
      patients (both males and females) will be included in each treatment arm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Skin Assessment of erythema, oedema/papulation, oozing/crusts, excoriations, and lichenification</measure>
    <time_frame>37 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skin Erythema measurement</measure>
    <time_frame>37 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transepidermal Water Loss (TEWL) measurement</measure>
    <time_frame>37 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS) assessment for itching (pruritus) of the treatment area</measure>
    <time_frame>37 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Global Assessment (PGA)</measure>
    <time_frame>37 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Group 2 Cis-UCA 5% emulsion cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 Placebo cis-UCA emulsion cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 Protopic® 0.1% ointment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1 Cis-UCA 2.5% emulsion cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cis-UCA 2.5% emulsion cream</intervention_name>
    <description>2.5% cis-UCA in emulsion cream base twice daily, amount of a fingertip per one hand (i.e. palm + thumb + fingers) area, applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area)</description>
    <arm_group_label>Group 1 Cis-UCA 2.5% emulsion cream</arm_group_label>
    <other_name>Cis-UCA 2.5%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cis-UCA 5% emulsion cream</intervention_name>
    <description>5% cis-UCA in emulsion cream base twice daily, amount of a fingertip per one hand (i.e. palm + thumb + fingers) area, applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area)</description>
    <arm_group_label>Group 2 Cis-UCA 5% emulsion cream</arm_group_label>
    <other_name>Cis-UCA 5%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for cis-UCA emulsion cream</intervention_name>
    <description>The placebo for cis-UCA product (emulsion cream base) twice daily, amount of a fingertip per one hand area applied topically as a thin layer on the affected skin area on of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area).</description>
    <arm_group_label>Group 3 Placebo cis-UCA emulsion cream</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Protopic® 0.1% ointment</intervention_name>
    <description>0.1% Protopic® twice daily, amount of a fingertip per one hand area applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area).</description>
    <arm_group_label>Group 4 Protopic® 0.1% ointment</arm_group_label>
    <other_name>Protopic®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent obtained prior to any screening procedure&#xD;
&#xD;
          -  Caucasian male or female patient&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Weight at least 45 kg&#xD;
&#xD;
          -  Patient with moderate or severe chronic atopic dermatitis&#xD;
&#xD;
          -  Good general health ascertained by medical history, physical examination and&#xD;
             laboratory determinations, showing no signs of clinically significant findings, except&#xD;
             chronic atopic dermatitis&#xD;
&#xD;
          -  Negative pregnancy test (premenopausal female patient) at screening and use of&#xD;
             adequate contraceptive measures (both male and female patients) throughout the study&#xD;
             and 30 days after the last cis-UCA dose&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of other significant skin disease, or skin manifestations of allergic illness&#xD;
             or other dermatologic condition, except chronic moderate or severe atopic dermatitis,&#xD;
             that would interfere with the trial assessments or compromise the patient's safety&#xD;
             according to the opinion of the Investigator&#xD;
&#xD;
          -  Present symptoms of other skin diseases, except chronic atopic dermatitis, that could&#xD;
             disturb the study assessment and evaluation of the skin&#xD;
&#xD;
          -  Current use of any active systemic medication for chronic atopic dermatitis within one&#xD;
             month&#xD;
&#xD;
          -  Current use of active topical medication in the planned investigational area for&#xD;
             chronic atopic dermatitis within two weeks&#xD;
&#xD;
          -  History of a sunny holiday, UV-light therapy or solarium use within one month before&#xD;
             beginning of study treatments, or planning such during the study or within 7 days&#xD;
             after the study&#xD;
&#xD;
          -  Allergy to cis-UCA, or any constituents of the placebo emulsion cream or any&#xD;
             constituents of Protopic® ointment&#xD;
&#xD;
          -  History of any skin-related cancer&#xD;
&#xD;
          -  Congenital or acquired immunodeficiency or ongoing therapy that cause&#xD;
             immunosuppression&#xD;
&#xD;
          -  Earlier participation in a clinical study performed with cis-UCA&#xD;
&#xD;
          -  Any clinically significant laboratory test result&#xD;
&#xD;
          -  Suspected current drug or alcohol abuse&#xD;
&#xD;
          -  Clinically significant illness during the 4 weeks prior to the first dose&#xD;
             administration&#xD;
&#xD;
          -  Any other condition that in the opinion of the Investigator would interfere with the&#xD;
             evaluation of the study results or constitute a health hazard for the patient&#xD;
&#xD;
          -  Unwillingness or doubtful capacity to comply with the protocol&#xD;
&#xD;
          -  Doubtful availability to complete the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sakari Reitamo, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital, Skin and Allergy Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Central Hospital, Skin and Allergy Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00200</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mehiläinen Medical Center Kuopio</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lohja Hospital, Clinic of Dermatology and Allergology</name>
      <address>
        <city>Lohja</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FinnMedi Oy</name>
      <address>
        <city>Tampere</city>
        <zip>FI-33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mehiläinen Medical Center Turku</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulssi Medical Center</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital, Department of Dermatology and Venereal Diseases</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <reference>
    <citation>Bieber T. Atopic dermatitis. N Engl J Med. 2008 Apr 3;358(14):1483-94. doi: 10.1056/NEJMra074081.</citation>
    <PMID>18385500</PMID>
  </reference>
  <reference>
    <citation>Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane ME, Moustafa M, Guy RH, Macgowan AL, Tazi-Ahnini R, Ward SJ. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol. 2009 Aug;129(8):1892-908. doi: 10.1038/jid.2009.133. Epub 2009 Jun 4. Review.</citation>
    <PMID>19494826</PMID>
  </reference>
  <reference>
    <citation>De Fabo EC, Noonan FP. Mechanism of immune suppression by ultraviolet irradiation in vivo. I. Evidence for the existence of a unique photoreceptor in skin and its role in photoimmunology. J Exp Med. 1983 Jul 1;158(1):84-98.</citation>
    <PMID>6223114</PMID>
  </reference>
  <reference>
    <citation>Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology. 1993;186(1):23-31.</citation>
    <PMID>8435513</PMID>
  </reference>
  <reference>
    <citation>Hanifin JM, Reed ML; Eczema Prevalence and Impact Working Group. A population-based survey of eczema prevalence in the United States. Dermatitis. 2007 Jun;18(2):82-91.</citation>
    <PMID>17498413</PMID>
  </reference>
  <reference>
    <citation>Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1989;144:13-4.</citation>
    <PMID>2800895</PMID>
  </reference>
  <reference>
    <citation>Wolkerstorfer A, de Waard van der Spek FB, Glazenburg EJ, Mulder PG, Oranje AP. Scoring the severity of atopic dermatitis: three item severity score as a rough system for daily practice and as a pre-screening tool for studies. Acta Derm Venereol. 1999 Sep;79(5):356-9.</citation>
    <PMID>10494710</PMID>
  </reference>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>March 21, 2011</study_first_submitted>
  <study_first_submitted_qc>March 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2011</study_first_posted>
  <last_update_submitted>June 20, 2012</last_update_submitted>
  <last_update_submitted_qc>June 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atopic dermatitis</keyword>
  <keyword>cis-urocanic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

